Global investment firm KKR has agreed to sell its approximately 38 percent stake in India-based pharmaceutical company Gland Pharma to Shanghai Fosun Pharmaceutical, a subsidiary of China-based conglomerate Fosun International, as part of Fosun’s acquisition of an 86 percent stake in the company. The transaction value will total as much as US$1.26 billion, of which KKR’s proceeds could reach US$576 million. KKR originally invested US$230 million in the company in 2014. Fosun’s acquisition is subject to regulatory approval.